Related Experiment Video

Updated: Jan 3, 2026

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

9.2K

Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials

Yunxin Lu1, Jiangmiao Li, Jiayi Xie

  • 1Guangxi Medical University.

Medicine
|November 15, 2019
PubMed

Insights

Sarpogrelate hydrochloride effectively improves peripheral artery disease (PAD) symptoms, enhancing walking distance and blood flow. This study confirms its efficacy and good tolerability in PAD patients.

Area of Science:

  • Vascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Peripheral artery disease (PAD) significantly impacts patient quality of life and mobility.
  • Conventional treatments for PAD offer limited efficacy and can have side effects.
  • Sarpogrelate hydrochloride is a selective 5-HT2A receptor antagonist with potential therapeutic benefits in vascular conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of sarpogrelate hydrochloride in patients with peripheral artery disease (PAD).
  • To compare the effects of sarpogrelate hydrochloride with conventional treatments on key clinical outcomes in PAD.
  • To assess the impact of sarpogrelate hydrochloride on inflammatory markers in PAD patients.

Main Methods:

  • A systematic literature search was conducted in major databases (PubMed, Embase, Cochrane Library, CNKI, CBM) for relevant randomized controlled trials (RCTs) published before January 1st, 2019.
  • Two independent reviewers assessed study eligibility, quality, extracted data, and synthesized findings.
  • A meta-analysis was performed using RevMan 5.3 software to pool data from 12 eligible RCTs.

Main Results:

  • Sarpogrelate hydrochloride significantly improved ankle-brachial index (ABI), dorsalis pedis artery blood flow, and pain-free walking distance (PFWD) compared to control groups.
  • Treatment with sarpogrelate hydrochloride led to a significant reduction in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels.
  • The analysis included 12 RCTs, demonstrating consistent positive effects across multiple outcome measures.

Conclusions:

  • Sarpogrelate hydrochloride is an effective treatment for improving symptoms in patients with peripheral artery disease (PAD).
  • The drug demonstrated good tolerability, with no significant adverse events reported in the included studies.
  • Sarpogrelate hydrochloride represents a promising therapeutic option for managing PAD.
Abstract

More Related Videos

A Rabbit Venous Interposition Model Mimicking Revascularization Surgery using Vein Grafts to Assess Intimal Hyperplasia under Arterial Blood Pressure07:02

A Rabbit Venous Interposition Model Mimicking Revascularization Surgery using Vein Grafts to Assess Intimal Hyperplasia under Arterial Blood Pressure

Published on: May 15, 2020

6.1K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.9K

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
209
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
268
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
300
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
321
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
406